Abstract
Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. Results: Statistically significant decreases in neovascular area (55.3%, P<0.001), which lasted through 16 weeks, and VC (59%, P <0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
| Original language | English |
|---|---|
| Pages (from-to) | 992-997 |
| Number of pages | 6 |
| Journal | Cornea |
| Volume | 32 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2013 |
Fingerprint
Keywords
- Corneal neovascularization
- Ranibizumab
- VEGF
ASJC Scopus subject areas
- Ophthalmology
Cite this
Topical ranibizumab as a treatment of corneal neovascularization. / Ferrari, Giulio; Dastjerdi, Mohammad H.; Okanobo, Andre; Cheng, Sheng Fu; Amparo, Francisco; Nallasamy, Nambi; Dana, Reza.
In: Cornea, Vol. 32, No. 7, 07.2013, p. 992-997.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Topical ranibizumab as a treatment of corneal neovascularization
AU - Ferrari, Giulio
AU - Dastjerdi, Mohammad H.
AU - Okanobo, Andre
AU - Cheng, Sheng Fu
AU - Amparo, Francisco
AU - Nallasamy, Nambi
AU - Dana, Reza
PY - 2013/7
Y1 - 2013/7
N2 - Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. Results: Statistically significant decreases in neovascular area (55.3%, P<0.001), which lasted through 16 weeks, and VC (59%, P <0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
AB - Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. Results: Statistically significant decreases in neovascular area (55.3%, P<0.001), which lasted through 16 weeks, and VC (59%, P <0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
KW - Corneal neovascularization
KW - Ranibizumab
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=84879089061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879089061&partnerID=8YFLogxK
U2 - 10.1097/ICO.0b013e3182775f8d
DO - 10.1097/ICO.0b013e3182775f8d
M3 - Article
C2 - 23407316
AN - SCOPUS:84879089061
VL - 32
SP - 992
EP - 997
JO - Cornea
JF - Cornea
SN - 0277-3740
IS - 7
ER -